Comparison of E. Coli strains producing human interleukin-36 receptor antagonist (IL-36RA) with coexpression of E. coli methionine aminopeptidase

Standard

Comparison of E. Coli strains producing human interleukin-36 receptor antagonist (IL-36RA) with coexpression of E. coli methionine aminopeptidase. / Kolobov, A. A.; Kondratyeva, E. V.; Kudling, T. V.; Karasev, M. M.; Kalinin, R. S.; Khizhina, A. A.; Protasov, E. A.; Nimiritsky, P. P.; Stefanov, V. E.; Petrov, A. V.

In: Russian Journal of Biopharmaceuticals, Vol. 9, No. 4, 2017, p. 20-26.

Research output: Contribution to journal › Article › peer-review

Author

Kolobov, A. A. ; Kondratyeva, E. V. ; Kudling, T. V. ; Karasev, M. M. ; Kalinin, R. S. ; Khizhina, A. A. ; Protasov, E. A. ; Nimiritsky, P. P. ; Stefanov, V. E. ; Petrov, A. V. / Comparison of E. Coli strains producing human interleukin-36 receptor antagonist (IL-36RA) with coexpression of E. coli methionine aminopeptidase. In: Russian Journal of Biopharmaceuticals. 2017 ; Vol. 9, No. 4. pp. 20-26.

BibTeX

@article{33c8e804766049a4ba20cc6fa1b6a64d,

title = "Comparison of E. Coli strains producing human interleukin-36 receptor antagonist (IL-36RA) with coexpression of E. coli methionine aminopeptidase",

abstract = "Generalized pustular psoriasis (GPP) is a rare and sometimes lethal form of psoriasis caused by series of mutations in the interleukin-36 receptor antagonist (IL-36RA) gene associated with its reduced expression or activity. Administration of exogenous IL-36RA can be a potent therapeutic approach for the treatment of GPP and other forms of psoriasis. Since cleavage of the starting N-formylmethionine residue from N-terminal end is needed for full biological activity of IL-36RA we have developed technology for producing IL-36RA lacking N-formylmethionine residue in E. coli. We have created a series of plasmids carrying the E. coli methionine aminopeptidase (MAP) gene under the control of different promoters for co-expression of IL-36RA and MAP and tested their effect on IL-36RA production. The highest production of IL-36RA with <3 % of un-processed molecules with uncleaved N-terminal formylmethionine residue has been shown for E. coli strain carrying the MAP gene under the control of arabinose-inducible promoter.",

keywords = "Interleukin-36 receptor antagonist (IL-36RA), Interleukins, Methionine, Methionine aminopeptidase (MAP), Recombinant protein",

author = "Kolobov, {A. A.} and Kondratyeva, {E. V.} and Kudling, {T. V.} and Karasev, {M. M.} and Kalinin, {R. S.} and Khizhina, {A. A.} and Protasov, {E. A.} and Nimiritsky, {P. P.} and Stefanov, {V. E.} and Petrov, {A. V.}",

year = "2017",

language = "English",

volume = "9",

pages = "20--26",

journal = "Russian Journal of Biopharmaceuticals",

issn = "2073-8099",

publisher = "Folium Publishing Company",

number = "4",

}

RIS

TY - JOUR

T1 - Comparison of E. Coli strains producing human interleukin-36 receptor antagonist (IL-36RA) with coexpression of E. coli methionine aminopeptidase

AU - Kolobov, A. A.

AU - Kondratyeva, E. V.

AU - Kudling, T. V.

AU - Karasev, M. M.

AU - Kalinin, R. S.

AU - Khizhina, A. A.

AU - Protasov, E. A.

AU - Nimiritsky, P. P.

AU - Stefanov, V. E.

AU - Petrov, A. V.

PY - 2017

Y1 - 2017

N2 - Generalized pustular psoriasis (GPP) is a rare and sometimes lethal form of psoriasis caused by series of mutations in the interleukin-36 receptor antagonist (IL-36RA) gene associated with its reduced expression or activity. Administration of exogenous IL-36RA can be a potent therapeutic approach for the treatment of GPP and other forms of psoriasis. Since cleavage of the starting N-formylmethionine residue from N-terminal end is needed for full biological activity of IL-36RA we have developed technology for producing IL-36RA lacking N-formylmethionine residue in E. coli. We have created a series of plasmids carrying the E. coli methionine aminopeptidase (MAP) gene under the control of different promoters for co-expression of IL-36RA and MAP and tested their effect on IL-36RA production. The highest production of IL-36RA with <3 % of un-processed molecules with uncleaved N-terminal formylmethionine residue has been shown for E. coli strain carrying the MAP gene under the control of arabinose-inducible promoter.

AB - Generalized pustular psoriasis (GPP) is a rare and sometimes lethal form of psoriasis caused by series of mutations in the interleukin-36 receptor antagonist (IL-36RA) gene associated with its reduced expression or activity. Administration of exogenous IL-36RA can be a potent therapeutic approach for the treatment of GPP and other forms of psoriasis. Since cleavage of the starting N-formylmethionine residue from N-terminal end is needed for full biological activity of IL-36RA we have developed technology for producing IL-36RA lacking N-formylmethionine residue in E. coli. We have created a series of plasmids carrying the E. coli methionine aminopeptidase (MAP) gene under the control of different promoters for co-expression of IL-36RA and MAP and tested their effect on IL-36RA production. The highest production of IL-36RA with <3 % of un-processed molecules with uncleaved N-terminal formylmethionine residue has been shown for E. coli strain carrying the MAP gene under the control of arabinose-inducible promoter.

KW - Interleukin-36 receptor antagonist (IL-36RA)

KW - Interleukins

KW - Methionine

KW - Methionine aminopeptidase (MAP)

KW - Recombinant protein

UR - http://www.scopus.com/inward/record.url?scp=85027488820&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85027488820

VL - 9

SP - 20

EP - 26

JO - Russian Journal of Biopharmaceuticals

JF - Russian Journal of Biopharmaceuticals

SN - 2073-8099

IS - 4

ER -

ID: 89839720